SOURCE: Equity News Circuit

Equity News Circuit

January 14, 2013 08:45 ET

Free Research Reports on BCRX, HALO, HOLX and TELK Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwire - Jan 14, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares surged over 12 percent on more than double the average daily volume Friday. BioCryst designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases.

Find out more about BioCryst Pharmaceuticals including full access to the free equity report at:

Halozyme Therapeutics, Inc. (NASDAQ: HALO) shares have soared over 33 percent in the past month. The company recently reported that it ended 2012 with a cash balance of approximately $100 million and expects 2013 net cash burn to be between $45 and $50 million.

Find out more about Halozyme Therapeutics including full access to the free equity report at:

Hologic, Inc. (NASDAQ: HOLX) is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products. Shares of the company have surged 8.5 percent in the past week.

Find out more about Hologic including full access to the free equity report at:

Telik, Inc. (NASDAQ: TELK) shares more than doubled on more than ten-times the average daily volume Friday. The company has recently reported that ezatiostat HCL (Telintra) has been granted orphan drug designation by the FDA.

Find out more about Telik including full access to the free equity report at:

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information